230 / 510
Cuidados
Continuos
229
Schwandt A1, Wood LS, Rini B, Dreicer R. Management of side effects associated with sunitinib
therapy for patients with renal cell carcinoma. Onco Targets Ther. 2009;2:51-61.
Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L et al. Hypothyroidism in patients with
metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007; 99:81-83.
Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus
a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl
J Med. 2001; 344: 783-792.
SeidmanA, HudisC, Pierri MK, Shak S, Paton V, AshbyMet al. Cardiac dysfunction in the trastuzumab
clinical trials experience. J Clin Oncol. 2002;20:1215-1221.
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al. Lapatinib plus capecitabine
for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355: 2733-2743.
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J et al; EMILIA Study Group. Trastuzumab
emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367(19):1783-91
Miles D, Baselga J, Amadori D, Sunpaweravong P, Semiglazov V, Knott A et al. Treatment of older
patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel:
subgroup analyses froma randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA).
Breast Cancer Res Treat. 2013; 142(1):89-99.
Kimby E. Tolerability and safety of rituximab. Cancer treat rev. 2005; 31: 456-473.
Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of
response with ipilimumab. J Clin Oncol 2012; 30:2691-7
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al. Safety, activity, and
immune correlates of anti-PD-1 antibody in cancer.
2012; 366:2443-54.
Moen MD, Mckeage K, Plosker GL, Siddiqui MA. Imatinib: a review of its use in chronic myeloid
leukaemia. Drugs 2007; 67: 299-320.
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A et al. Temsirolimus, interferon alfa,
or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-2281
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S et al; RECORD‟1 Study Group.
Phase3 trial of everolimus formetastatic renal cell carcinoma : final resultsandanalysisof prognostic
factors. Cancer 2010;116:4256-4265
Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS et al. Survival in BRAF V600-
mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012 ;366(8):707-14
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ et al. Crizotinib versus chemotherapy in
advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385-94
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.